Newron continued to made steady progress in H118. A fuller debrief of pipeline assets including sarizotan (Rett syndrome) and Evenamide (schizophrenia) will take place at the R&D day in NYC, scheduled for 31 October. Royalty income from sales of Xadago (Parkinson’s disease, PD) rose by 54% to €2m, driven mainly by increased sales in the EU and Switzerland. However, the US sales contribution remained small (launched by partner US WorldMeds in H217). In H118 Newron reported an op
11 Oct 2018
Newron Pharmaceuticals - Next up - R&D day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Newron Pharmaceuticals - Next up - R&D day
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
11 Oct 2018 -
Author:
Dr Susie Jana -
Pages:
3
Newron continued to made steady progress in H118. A fuller debrief of pipeline assets including sarizotan (Rett syndrome) and Evenamide (schizophrenia) will take place at the R&D day in NYC, scheduled for 31 October. Royalty income from sales of Xadago (Parkinson’s disease, PD) rose by 54% to €2m, driven mainly by increased sales in the EU and Switzerland. However, the US sales contribution remained small (launched by partner US WorldMeds in H217). In H118 Newron reported an op